GANX
Gain Therapeutics, Inc.
Key Financials
Net Income
$-20161099
↑ 1.2%
Revenue
$55180
0.0%
Operating Income
$-18710702
↑ 8.1%
EPS (Diluted)
$-0.61
↑ 31.5%
Total Liabilities
$4.3M
↓ 11.1%
Total Assets
$22.8M
↑ 88.2%
Shareholders' Equity
$18.6M
↑ 152.9%
Cash & Equivalents
$20.8M
↑ 100.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| 8-K | 9/28/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GANX |
| Company Name | Gain Therapeutics, Inc. |
| CIK | 1819411 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (301) 500-1556 |